Cure of anti-cardiolipin antibody positivity is considered to be a conversion to negative, and the time of cure is determined by the progress of the disease and the state of disease control. Anti-cardiolipin antibodies are autoantibodies that use negatively charged cardiolipin on platelets and endothelial cell membranes as target antigens, and are among the antiphospholipid antibodies commonly found in phospholipid syndrome, systemic lupus erythematosus and other autoimmune diseases. Some patients with phospholipid syndrome and lupus erythematosus are mild and do not have multisystem involvement, and only develop positive anti-cardiolipin antibodies, which may turn negative at the follow-up observation after 3 months, but some patients may have positive anti-cardiolipin antibodies for life. If the patient does not have thrombocytopenia, hypercoagulable blood, high risk factors for thrombosis, or fertility requirements, only positive anticardiolipin antibodies can be temporarily left untreated. Patients with positive anti-cardiolipin antibodies need to be followed up regularly, and it is recommended that they be reviewed once every six months or so, and that they go to the hospital promptly if symptoms appear.